This webinar takes place on Thursday December 11th  between 16.00 and 16.30 CET / 15.00-15.30 GMT / 10.00-10.30 AM EST / 7.00-7.30 AM PST.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

Abstract:

Antisense oligonucleotides (ASOs) are being developed as therapeutics for central nervous system disorders. Due to the lack of blood–brain barrier penetrance, they must be delivered via intrathecal administration to achieve effective target engagement in the brain or spinal cord, which among other things can trigger acute neurobehavioral side effects. Although efficacious and safe ASOs already exist, safety assessment for ASOs is still very much a developing area of research. While mouse models are frequently used to assess acute tolerability, predictive in vitro models has the potential to eliminate acutely neurotoxic ASOs early in the drug discovery process, and more precise selection of ASOs to progress to in vivo studies.

Based on the above, Cellectricon sought out to develop an assay for acute onset ASO-induced neurotoxicity based on our proprietary optical electrophysiology platform as well as published work. In this webinar, we present the outcome, a predictive in vitro assay for assessment of acute onset oligonucleotide-induced toxicity.

presented by:

Johan Pihl, CSO

Johan joined Cellectricon in 2005 and has been in R&D as well as commercial positions at the company. He has been involved in the development of Cellectricon’s proprietary technology platforms and intellectual property. Prior to his role as Chief Scientific Officer at Cellectricon, he was developing and overseeing the discovery services as Chief Operating Officer. Johan has a PhD in Chemistry from Chalmers University of Technology, Gothenburg, Sweden, and is the author and co-author of numerous scientific publications and patents.